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Abstract: Carbonic anhydrases (CAs) are a superfamily of metalloenzymes widespread in all life,
classified into seven genetically different families (α–θ). These enzymes catalyse the reversible
hydration of carbonic anhydride (CO2), generating bicarbonate (HCO3−) and protons (H+).
Fifteen isoforms of human CA (hCA I–XV) have been isolated, their presence being fundamental for
the regulation of many physiological processes. In addition, overexpression of some isoforms has been
associated with the outbreak or progression of several diseases. For this reason, for a long time CA
inhibitors (CAIs) have been used in the control of glaucoma and as diuretics. Furthermore, the search
for new potential CAIs for other pharmacological applications is a very active field. Amino acids
constitute the smallest fundamental monomers of protein and, due to their useful bivalent chemical
properties, are widely used in organic chemistry. Both proteinogenic and non-proteinogenic amino
acids have been extensively used to synthesize CAIs. This article provides an overview of the different
strategies that have been used to design new CAIs containing amino acids, and how these bivalent
molecules influence the properties of the inhibitors.
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1. Introduction
The interconversion between CO2 and HCO3− is fundamental for the successful flow of
biochemical processes in all living cells [1]. Metabolic conversion is ensured by the hydration of
carbonic anhydride which leads to the corresponding soluble ion, bicarbonate, and the release of
a proton [2,3]. Due to the high number of physiological process in which these chemical species
are essential, the optimal balance between them is vital for all life forms [2,4–7]. This equilibrium
is regulated by a superfamily of metalloenzyme, the carbonic anhydrases (CAs, EC 4.2.1.1) [1].
By accelerating this normally slow reaction [8], CAs fulfil the metabolic needs connected to
CO2/bicarbonate and protons [2,4,6]. In fact, CAs are among the most effective catalysts known
in nature [3] as their turnover number (kcat) can reach the value of 106 s−1 [9]. Seven genetically
different families of these ubiquitous enzymes were identified (α–η) [2]; all of them possess a bivalent
metal ion fundamental for catalysis, as the apoenzyme is devoid of activity [3]. Mammalian CAs
belong to the α-family and they are characterized by the presence of a bivalent zinc ion within the
active site [1]. This Zn2+ coordinates a water molecule, or a hydroxide ion in the activated form of the
enzyme, making the hydration of CO2 a fast process [1,2,10].
Human carbonic anhydrases (hCAs) are widespread in the organism, varying for tissue
distribution and subcellular localization. Fifteen α-isozymes (hCA I–XV) have been isolated and
characterized so far, but only 12 of them are catalytically active [4,5,11]. hCAs are involved in pH
and CO2 homeostasis but also in the regulation of many crucial physiological processes, such as
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gluconeogenesis, lipogenesis or electrolyte secretion in a variety of tissues and organs [2,4–6].
hCA I and II are the widest expressed isoforms and, together with hCA IV, were identified in
the anterior chamber of the eye, being responsible in this organ for the production of bicarbonate,
the main constituent of aqueous humor [5,12]. hCA IX and XII can be defined as tumor-associated
proteins, due to their massive expression in many hypoxic cancers [4,5,13,14]. These isozymes
are transmembrane proteins, with an extracellular catalytic domain; they are fundamental for the
survival of tumor cells under stressful conditions, due to their ability to generate a differential pH
microenvironment, resulting in increased tumor growth [5,13,15,16]. While CA activators do not have
for the moment any approved pharmacological application [17], CA inhibitors (CAIs) are commonly
used in therapy, mainly as anti-glaucoma agents, anti-epileptics and diuretics, while other therapeutic
applications are still under investigation (anti-cancer, anti-obesity agents, and others) [5,12,18–21].
2. Carbonic Anhydrase Inhibitors (CAIs)
In the CAs active site the bivalent metal ion normally possesses a tetrahedral geometry, since it
interacts with three amino acids moieties and coordinates the water molecule/hydroxide ion. In α-CAs,
the Zn2+ ligands are three histidine residues (Figure 1) and, together with other key amino acids, they form
a very particular and strictly conserved catalytic site within each family of carbonic anhydrase [1–3].
It is, therefore, possible to recognize two different regions in the cavity of the active site, a first half
composed exclusively of hydrophobic amino acids and a second one where only hydrophilic residues are
present [22], leading to an amphiphilic site architecture [2].
Figure 1. (a) Schematization of the interaction between a generic sulfonamide and the
Zn2+ in the carbonic anhydrase (CA) active site. Sc = Scaffold (b) X-ray structure of
(S)-4-(4-acetyl-3-benzylpiperazine-1-carbonyl)-benzenesulfonamide (49b, discussed in Section 7,
shown with carbon atoms in yellow,) bound in the active site of hCA I (Protein Data Bank (PDB) entry
6EVR) [23]. The sulfonamide group interacts with the Zn2+ (dark grey sphere) which is coordinated by
three His residues (in purple).
Depending on the mechanism of action, five different classes of CAIs are known (Figure 2) [21,24]:
1. Zinc binders, i.e., compounds that chelates the bivalent metal ion of the active site. This interaction
interrupts the coordination between the Zn2+ atom and the water molecule/hydroxide ion and
consequently blocks the enzymatic activity [21,24,25]. The mechanism is schematized in Figure 1a:
the scaffold of these molecules (reported as “Sc”) may interact with one or both the halves of
the active site, stabilizing the interaction with the ion in a tetrahedral geometry. This is the most
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important class of inhibitors, to which belong sulfonamides and their isosteres (sulfamates or
sulfamides), dithiocarbamates, hydroxamate, etc. [3,24]. Sulfonamides are the most widely
studied CAIs with at least 20 compounds in clinical use for decades [24]. Some examples
(acetazolamide, brinzolamide and dorzolamide) are shown in Figure 2.
2. Compounds that anchor to the-zinc coordinated water molecule/hydroxide ion, such as phenols
and polyamines [3,24,26].
3. Compounds occluding the entrance of the active site (coumarins and their isosters) [3,24,27].
4. Compounds that bind out of the active site, such as 2-(benzylsulfonyl)benzoic acid [24,28].
5. CAIs acting without a known mechanism, such as secondary/tertiary sulfonamides, imatinib, etc. [3,24].
Figure 2. The five classes of carbonic anhydrases inhibitors (CAIs).
As we can note in Figure 2, the five types of inhibitors possess various structures;
chemical differences in their pharmacophoric moieties result in different structure activity relationships.
Despite this premise, a common problem of CAIs, and in particular of zinc binders, is the lack of
selectivity for a specific isoform or the absence of a good water solubility. Many efforts have been
made in the last few decades to explore chemical modifications of the CAI structures that could have
a positive effect on these properties. In particular, the aim of this review is to provide an overview of
the investigated applications of amino acid moieties in the resolution of these problems. This paper is
focused on CAIs that carry amino acids or their derivatives in their structures, and how these molecules
influence the properties of these inhibitors. Both proteinogenic and non-proteinogenic amino acids
have been considered in this analysis and, depending on their synthetic use, five different strategies
have been identified.
Amino acids are the primary building blocks of proteins and, of the over 300 naturally occurring,
22 constitute the monomer units of these biological molecules [29]. Amino acids are widely used in
organic chemistry; they constitute the smallest fundamental pieces in solid phase peptide synthesis but,
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due to their characteristics, they are also commonly used in solution synthesis [30]. Their properties
range from acidic to basic due to the contemporary presence of a carboxyl and an amino group that,
in addition, allow the possibility to easily generate different kind of connections to link the amino acid
to other molecules. Beside this, a number of amino acids have reactive groups in their side chains that
can be chemically modified [29]. Furthermore, the use of natural α-amino acids allows a broad range
of derivatives to be obtained, with the possibility, starting from enantiopure amino acids, to further
define the stereochemistry of the side chain. Thanks to ionizing properties that could be exploited to
form salts, the carboxy and the amino moieties also ensure good water solubility to these derivatives.
3. Amino Acyl as a Water-Solubilizing Tail
Glaucoma is a group of optical neuropathies associated with progressive loss of visual field,
leading to visual impairment and blindness. There is a general agreement that increased intraocular
pressure (IOP) is the most important risk factor for the outbreak and progression of this disease [12,31].
It was demonstrated [32] that in glaucomatous patients the inhibition of CAs leads to a reduction of IOP
and an amelioration of the symptoms. Due to the wide distribution of the different CA isozymes in the
body, the administration of systemic inhibitors usually elicits undesired side effects [12,31,33]. For this
reason, the treatment of glaucoma is mainly performed with topically administered CAIs [12,34];
two drugs, brinzolamide and dorzolamide (Figure 2), are available in the clinic. These two inhibitors
often produce local side effects, such as ocular burning, a stinging sensation, superficial punctuate
keratitis, blurred vision and reddening of the eye. These problems are mainly due to the strong acidic
pH of their solution, as they are both administered as hydrochloride salts [12,35].
In order to reduce these inconveniences, many efforts have been made to develop new topically
administered CAIs. Among others, a method investigated in depth has been the attachment
of water-solubilising tails to known effective CAIs. This method is particularly important for
sulfonamides, very potent anti-glaucoma agents often endowed with low water-solubility.
The use of amino acids for this purpose was investigated by many research groups, with a broad
variety of approaches. The bivalent chemical nature of these synthons allows two possible series of
products to be obtained, the amino-substituted compounds 1 and the carboxy derivatives 2 (Figure 3).
In 1, the free carboxyl group can be treated with strong bases to give salts or can be further functionalized.
Also compounds 2 can be endowed with good hydrophilic properties thanks to the free basic amino
group: such compounds are ideal for ophthalmologic applications, since the water solutions of their salts
with strong acids have a weakly acidic pH, preferred over those of alkaline pH [36].
Figure 3. General structure of amino acids functionalised on the amino group (1) or on the carboxy moiety (2).
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Antonaroli et al. [37], Blackburn’s [38] group, and later Barboiu et al. [39] reported some structural
manipulations of acetazolamide, where the N-acetyl residue was substituted with different aminoacids,
giving compounds with general formula 3 and 4 (Figure 4). The structural modification of this
first-generation CA inhibitor led to interesting products: the salts of compounds 3 and 4 showed a very
good water solubility, associated with effective inhibitory activities against the enzyme. As an example,
the β-alanyl derivatives 3a was three times more potent on hCA II and over 100 times on hCA I than
dorzolamide. Only against the isozymes hCA IV, this compound showed an activity three times lower
than the reference drug.
Figure 4. Structure of acetazolamide analogues 3 and 4.
A similar approach was also investigated by Scozzafava et al. in two separate works [36,40]. Twenty six
different sulfonamides containing amino, imino, hydrazino or hydroxyl groups (general formula 5, Figure 5)
reacted with the carboxy moiety of five different glycine derivatives (glycine, sarcosine, creatine, gly-gly and
β-alanine). The extremely versatile nature of the carboxyl group allowed a large library of new compounds
(general formula 6) to be generated, differing not only in the structure of the two reagents, but also for the
characteristics of the new formed carboxy-derived bonds (i.e., amidic, esteric and hydrazidic bonds).
Figure 5. General structure and some examples of the compounds investigated by Scozzafava et al. [36,40].
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All the 130 obtained compounds 6 possess very good water solubility as salts of strong acids.
They showed a wide range of inhibitory activities against three CA isozymes, hCA I, II and bCA
IV. The addition of the aminoacyl/dipeptidyl moiety generally led to an increase of CA inhibitory
properties with respect to the corresponding parent sulfonamide. The five amino acid derivatives 6a–f
can be taken as an example: they were from 3 to 18 times more potent than the precursor 7. In addition,
the most active compounds of the series were selected for in vivo studies. The topical application
directly into the eye showed IOP-lowering effects both in normotensive and glaucomatous rabbits,
a frequently used animal model of glaucoma [41,42]. As an example, the acetazolamide derivative 6f
was a more efficient and long-lasting IOP-lowering agent compared to the reference drug dorzolamide.
It is also possible to enhance the basic nature of the free NH2 group by conversion into a guanidine
moiety, as reported by Ceruso et al. [43]. The carboxyl group of two amino acids, Nα-acetylysine
and γ-aminobutyric acid, was connected to a benzyl or phenetylamine carrying a sulfonamide group,
obtaining a first series of basic compounds (8a and 9a, Figure 6); subsequently the amino groups were
treated with N,N′-di-Boc-N”-trifluoromethane-sulfonylguanidine, obtaining the guanidine derivatives
8b and 9b. This transformation enhanced the solubility of the hydrochloride salts but not their potency,
since the guanidine derivatives showed Ki values almost in the same range of the amino-precursor
on hCA I, hCA II and Porphyromonas gingivalis γ-CA. The same products were also tested against the
two tumor-associated isoforms hCA IX and hCA XII [44]. Due to their transmembrane localization
and their extracellular catalytic domain, the use of hydrophilic CAIs, endowed with poor cellular
permeability, could in principle selectively target these isoforms. The effect of the terminal guanidine
moiety on activity was relevant only on hCA XII for some GABA-derivatives: as an example, 9c showed
a Ki value almost nine times lower than the corresponding amino precursor.
Figure 6. Structure of benzenesulfonamide derivatives 8 and 9.
The addition of the amino acid by means of the amino group, instead of the carboxy one,
was investigated by Casini et al. in two separate, but closely related papers [35,45]. Two series
of sulfonamides were synthesized by the reaction of 4-isothiocyanatobenzenesulfonamide 10a or
4-isothiocyanatomethyl-benzenesulfonamide 10b with 33 different amino acids and oligopeptides,
forming a thioureido linkage between these two portions (general formula 11, Figure 7). Many newly
obtained compounds possess very good water-solubility properties; the presence of at least one free
carboxyl group allows the easy formation of sodium salts. Their solutions showed pH values in the
range of 6.5–7.0 and, due to these optimal values, no or modest eye irritation effects were observed.
Strong inhibitory properties were detected for many derivatives against hCA I, hCA II and bCA IV
and, thanks to their strong tendency to concentrate in ocular fluids and tissues, almost 20 compounds
showed effective IOP-lowering properties after topical administration.
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Figure 7. Thiourea derivatives studied by Casini et al. [35,45].
Using 4-carboxybenzenesulfonamide 12 or 4-chloro-3-sulfamoylbenzoic acid 13 (Figure 8)
Mincione et al. [46] synthesized a new series of inhibitors, where different amino acids or dipeptides
were directly linked to the sulfonamide through an amidic bond (general formula 14 and 15, Figure 8).
As previously mentioned for the thioureido derivatives 11, many newly obtained compounds were
able to inhibit three CA isozymes (hCA I, hCA II and bCA IV) showing K1 values in the nanomolar
range. The corresponding carboxylate salts, with their good water-solubility, were investigated in
IOP-lowering in vivo experiments. The topical administration of these solutions, which possessed pH
values in the neutrality range, showed very important and long lasting IOP-lowering effects in rabbits,
stronger and longer-lasting on the glaucomatous animals than on the normotensive ones.
Figure 8. Sulfamoylbenzamides of amino acids and dipeptides.
4. The Tail Approach to Carbonic Anhydrases Inhibitors Using Amino Acids
As reported in Section 2, CAIs fall into five categories, according to their mechanism of action [21].
Probably, the most important CAIs problem is the lack of selectivity for a specific isoform, due to the
well conserved catalytic site among the isozymes. A possible method to gain selectivity is the so called
“Tail Approach” [21,24,25,33]. This strategy is based on the structural modification of a portion on the
inhibitor (Tail in Figure 1a), usually in a position not fundamental for the Zn-chelating activity, that could
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potentially interact with the regions surrounding the active site, where the amino acids variability is
higher. On this basis, the chemical differences in the amino acids’ side chains and the possibility to use
also “non-α” amino acids make these molecules optimal candidates for the “tail” role (Figure 9). As is
simple to imagine, there is an extremely high variety of possible synthetic pathways that can be used to
obtain different compounds by using the carboxy (as in 16) or the amino moiety (as in 17).
Figure 9. General structure of CAIs decorated with amino acids through the carboxy group (16) or the
amino moiety (17).
An interesting work, focused on the investigation of enzyme-inhibitor interactions, was performed
by the groups of Whitesides and Christianson [47–49]: in order to explore if secondary interactions
away from the active site could influence inhibitory activity, they prepared three series of derivatives
(general formula 18–20, Figure 10). At first these researchers synthesized a series of oligolgycine-
and oligo(ethy1eneglycol)-linked benzenesulfonamides (18), whose dissociation constant on bCA
II (Kd, measured by means of a competitive fluorescence-based assay) was found in the high
micromolar range and independent of the polymer length [48]. Later, they condensed several
tripeptides to 4-sulfamoylbenzoic acid, obtaining compounds with general formula 19, endowed with
Kd values in the nanomolar range on hCA II [49]. The complex with 19a was analyzed by
means of X-ray crystallography: the phenylglycine moiety was placed near Phe131 and Pro202,
establishing hydrophobic interactions and validating the initial design.
Figure 10. General structures of the compounds investigated in [47–49].
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The compound carrying three ethylene glycol moieties (18a) was, therefore, chosen by Boriack
et al. as primary scaffold for their final investigation [47]. Different amino acids were added to the
terminal portion of the poly-ethylene glycol chain; with this design compounds 20 were obtained,
carrying a free amino group, and endowed with increased activity (Kd values from 2 to 10 times lower
than the parent compound 18a). This flexible and quite long linker was able to direct the amino acid
toward enzyme surfaces far from the zinc ion, in a region where it can stabilize the binding through side
interactions. Since in this series of compounds the best terminal pendants were lipophilic amino acids,
these researchers suggested that the linker chain delivered the terminal group close to a hydrophobic
region composed by Pro201, Pro202 and Leu198, even if the X-ray structures (Protein Data Bank (PDB)
codes 1CNW, 1CNX and 1CNY) did not reveal ordered folds of the ethylene glycol linker.
Garaj et al. [50] used the tail approach on a series of novel sulfonamides incorporating the
1,3,5-triazine moiety, and obtained a small set of compounds with affinity from nanomolar to
micromolar on hCA I, hCA II and hCa IX. In this series, glycine (m = 1) and β-alanine (m = 2)
derivatives 21 (Figure 10) showed good potency on hCA IX, with Ki values 20–30 times lower than
on hCA I and II, but independently of m. The library of these derivatives was later expanded by
Carta et al. [51], who investigated, among several substituents, a wider number of amino acids in
position 2 or 2,4 of the triazinyl ring (general formula 22, Figure 11). Many compounds showed
nanomolar Ki values against the transmembrane tumor-associated CA IX and XII, in addition to CA
XIV; the latter isoform is not associated with cancers but is widespread in many tissues such as the
kidney, liver and brain among others [3]. As for 21, higher Ki values were found against the off-target
isoforms hCA I and II. In some cases some selectivity was obtained: as an example, compound 22a
showed a Ki 0.96 nM on hCA IX, being on this isoform 6, 10, >550 and >1300 times more potent than on
hCA XII, XIV, II and I, respectively. Two derivatives (22b and 22c) displayed significant activity also on
hCA VII. The binding of the analogue 22d was analyzed by means of X-ray crystallography (PDB 2ILI)
on hCA II: the chlorine atom was engaged in contacts with the side-chain atoms of Ile91 and Gln92
while the triazinyl ring made pi-stacking interactions with the phenyl ring of Phe131. The glycine
moiety was directed toward the rim of the active site, apparently not engaged in positive interactions.
Figure 11. General structure of triazinyl derivatives 21-22.
Amino acids were the ideal candidates for the side decoration of fullerene (C60), an atypical
potential CA inhibitor [52]. Fullerene derivatives possess some interesting properties: as an example,
fullevir [53], the sodium salt of fullerene-polyhydro-polyaminocaproic acid, displays significant
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antiviral, antibacterial and anticancer activity [54–57]. In addition, fullerene possesses a diameter of
about 1 nm, a size similar to the width of the active site entrance of most CA isozymes [58]. In order to
improve the very low water solubility and to insert groups that could provide selectivity by interacting
with residues of the entrance of the catalytic site, some phenylalanine derivatives were investigated as
fullerene pendants (general formula 23, Figure 12). Inhibitory activity was measured on a panel of hCA
isozymes (I, II, III, IV, VA, VB, VI, VII, IX, XII, XIII, XIV, XV), finding Ki values in the micromolar range
and no selectivity. Computational studies suggested that the inhibition mechanism is the occlusion of
the active site through the fullerene cage; it is, therefore, possible that this bulky and extremely rigid
scaffold prevents pendants from interacting with crucial amino acid residues, located in a deeper area
of the enzyme. This hypothesis seems confirmed by the very low difference in activity measured for
the synthesized fullerenes, including those not carrying amino acids pendants.
Figure 12. Fullerene-amino acid derivatives studied in [52].
A wide investigation of the “amino acid-tail approach” was performed by Küçükbay et al.
They synthesised carboxy-derivatives linking a N-protected amino acid to three different types of CA
inhibitors, obtaining amino-sulfonamides (24–26) [59], coumarins (27, 28), tetrahydroquinolinones 29 [60]
and benzothiazoles 30, 31 [61] (Figure 13).
Figure 13. Structure of the compounds investigated by Küçükbay et al. [59–61].
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Compounds 24–31 were tested against four CA isozymes (hCA I, II, IV and XII). The results were
extremely different between the three series. Sulfonamides 24–26 were the most active and sensitive to
structural variation, with Ki values mainly in the nanomolar range. By analysing the data, it is indeed
possible to note appreciable differences in activity when the N-protected amino acid was varied, even if
it is not simple to infer clear structure activity relationships. Few compounds were endowed with
some selectivity toward CA XII: on this isoform, for instance, compound 24a (Ki 9.5 nM) is 18, 47 and
201 times more potent than on CA IV, II and I, respectively.
Dihydroquinolinones 29 were inactive on the four isoforms, while coumarins 27 and 28 showed
micromolar Ki values only against hCA IV and XII [60]. As a matter of fact, this scaffold is already
known as preferential inhibitor of the tumor-associated hCA IX and XII [24,62,63]; the addition
of an amino acid tail abolished activity against the off-target isozymes hCA I and II. Moreover,
two derivatives (27a and 28a, Figure 13) were completely inactive also against hCA IV, thus showing
selectivity for hCA XII.
Benzoathiazoles 30 and 31 showed micromolar Ki values almost exclusively on the ubiquitous
isoform hCA I, with only three compounds being active also on hCA II. Surprisingly, one N-Boc-glycine
derivative (30a, Figure 13) showed activity also on hCA XII, with a Ki value nine time lower than that
registered against hCA I. Another compound, 31a, showed activity only on CA II, albeit with low
potency (Ki 10 µM).
It is interesting to note that compounds 24–31 inhibit CA by different mechanisms, owing to
the diverse scaffolds carrying the amino acid tail. The analysis of this research suggests that the
“amino acid tail approach” could be interesting for the derivatization of different kind of CA inhibitors.
The pretty simple and quick synthetic methods available to link an amino acid moiety to a generic
group allow a large library of structurally-related compounds to be obtained, from which it is easy to
study the effects of the substitution on activity. In addition, the hydrophilic nature of these molecules
could be useful for enhancing their water-solubility.
5. Amino Acids as Linkers
The bifunctional chemical nature of the amino acids can be used to link together two different
substituents, generating molecules with new characteristics. A generic sulfonamide could indeed
be connected to another chemical entity through these bivalent linkers (generic formula 32 and 33,
Figure 14). The possibility to protect the amino or the carboxyl moieties, in addition to their different
reactivity, allows the easy and selective functionalization of these chemical groups. This strategy could
be considered an upgrade of the “amino acid tail approach”, on these compounds, beyond the amino
acid chain, the side group (SG in Figure 14) represents an additional point of variation.
Figure 14. General structure of sulfonamide CAIs having an amino acid as linker.
A first example is the previously cited work of Barboiu et al. [39], where compound 3a (Figure 4)
was further functionalized on the free NH2 with various pendants, affording a wider series of
5-substituted thiadiazole-2-sulfonamides (general formula 34, Figure 15). In order to obtain derivatives
with different physico-chemical properties, compound 3a (Figure 4) was reacted with 30 different
electrophilic reagents (i.e., alkyl/aryl sulfonyl chlorides or fluorides, sulfonic acid cyclic anhydrides
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or acyl chlorides) and the corresponding products were then tested against isozymes hCA I, II and
bCA IV. This series is characterized by a potent inhibitory activity on hCA II, most of the measured Ki
values being in the low nanomolar range on this isoform, but in the micromolar range against hCA I
and bCA IV. We can cite derivative 34a as an example: the Barboiu group determined a Ki of 0.75 nM
on hCA II while the values measured against hCA I and bCA were, respectively, 125 and 100 nM.
There is indeed a strong selectivity for the human isoform II confirming the evidence that this scaffold
could be a promising candidate for the development of selective hCA II inhibitors.
Figure 15. Acetazolamide derivatives studied by Barboiu et al.
Kolb et al. patented a series of radioactively labelled sulfonamides [64], with high affinity for
hCA IX, that could be potentially used as positron emission tomography (PET) tracers for imaging
the hCA IX expression on the surface of cancer cells. The group identified a benzothiazole or
p-substituted phenyl ring as ideal aromatic scaffolds to carry the sulfonamidic moiety and used
click-chemistry to functionalize the inhibitor portion with different groups; a 18F atom was inserted on
this tail as radionuclide. They designed four series of compounds and two of them (general formula
35 and 36, Figure 16) were prepared using an amino acid derivative (azido acid) as building block
for the construction of the triazole central ring. In addition, the use of a second amino acid as
radionuclide-carrying portion was investigated. With such a strategy, these researchers were able
to obtain a large library of compounds, with different chemical characteristics and many possible
points of structural variation. Furthermore, the use of L or D amino and azido acids allowed the
stereochemical control of the side chain and, consequently, its orientation toward the regions of the
enzyme. One of the most promising compound, VM-4037A (35a), was tested in tumor xenograft
models expressing hCA IX [65]. In addition, its biodistribution and radiation dose were determined in
healthy human volunteers [66]; the high uptake of 35a in liver and kidney indicated that the compound
was not suitable for the detection of hCA IX in these tissues.
Figure 16. Sulfonamide derivatives carrying a triazole-amino acid as linker.
A quite different approach was used by the Matulis group [67,68] to derive p-amino
benzenesulfonamide. By reacting the p-amino group with acrylic acid, Rutkauskas et al. obtained
a series of compounds where a β-alanyl moiety is directly linked to the aromatic scaffold
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(general formula 37 and 38, Figure 17). In this instance, the amino acid linker was generated in situ
and then functionalized on the free β-carboxy moiety. In addition, the versatile nature of this group
allowed its transformation into heterocycles, such as triazoles, oxadiazoles or thiadiazoles [67]. Only in
a few instances the activity of this first series of compounds (Kd values determined by a fluorescent
thermal shift assay on CA I, II, VI, VII, XII and XIII) was below 1 µM. The functionalization of the
alanyl nitrogen and substitution on the benzenesulfonamide ring were also investigated, adding other
possible points of variation [68]. As one can imagine, this large number of different products showed
a wide range of activities, with Kd values on CA I, II, XII and XIII from nanomolar to micromolar.
The selectivity of some compounds was further tested on a larger panel of hCAs, with some interesting
findings. For instance, 39 (Figure 17) showed good potency on CA VB and CA IX (Kd = 5 and
43 nM, respectively) while being almost inactive on the other isoforms. The crystallographic studies
performed on 37a and hCA II allowed the way the flexible β-alanyl linker was folded in the enzyme
cavity (PDB code 4Q6E) to be understood.
Figure 17. Structure of the β-alanine derivatives studied by the Matulis group.
Ceruso et al. [69] extended the chain using a γ-aminobutiric acid moiety as linker between
two different benzenesulfonamides and various aromatic pendants. Compared to 37, the amino
acid orientation was inverted, leaving a free amino group that was reacted with aryl isocyanates.
The molecules obtained (general formula 40, Figure 18) were tested against 13 hCA isoforms,
showing good inhibition potency against hCA I, II, VII and XII. This serie lacks isoform selectivity,
but a deeper investigation on the effects of the chain length and of the chemical nature of the terminal
aromatic pendants could potentially lead to more interesting derivatives.
Figure 18. Benzenesulfonamide derivatives incorporating a GABA moiety.
Moeker et al. [70] studied an innovative approach using a sulfamate as zinc binding group (ZBG).
These researchers designed a series of glycosylated compounds with poor membrane permeability
that could potentially lead to hCA IX selective inhibitors, owing to the extracellular localization of this
enzyme. The general structure of these derivatives (41, Figure 19) is characterized by a free or acetylated
glucose moiety, linked to a panel of primary and secondary amino alcohols through a sulfonamide
bridge. Two hydroxylated amino acid (L-serine methyl ester and L-4-(R)-hydroxyproline methyl
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ester) were investigated as hydroxylated linkers and transformed into the corresponding sulfamate
(41a and 41b). In such a way, the ZBG is directly placed on the chiral amino acid side chain. All the
synthesized molecules showed nanomolar K1 values against the tumor-associated isoforms hCA IX
and XII [5,13], and lower potency against the off-target isozymes hCA I and II. Particularly interesting
is the proline-derivative 41a, with Ki values of 2 and 1 nanomolar respectively on hCA IX and XII and
more than 350 times lower potency on hCA I and II. This innovative method is interesting not only
from a synthetic point of view, but also because it allows the ZBG to be kept fixed and functionalizes
both the amino and carboxy portions of the amino acid with different residues.
These examples demonstrate that a chiral amino acid can serve either as building block either as
linker between side pendants.
Figure 19. Sulfamate derivatives studied by Moeker et al. [70].
6. Dual Carbonic Anhydrase (CA) and Matrix Metalloproteinase (MMP) Inhibitors
Matrix metalloproteinases (MMPs) are zinc-containing endopeptidases, capable of degrading the
extracellular matrix proteins; up-regulation of specific isoforms is associated with various pathologies,
including some metastatic cancers [71–73]. These enzymes are potently inhibited by hydroxamates,
but also other chemical groups are known to be effective Zn-chelating agents [74]. Since hCA IX
and XII are overexpressed in tumors [5,13], the simultaneous inhibition of both enzymes should give
a synergic effect.
On these basis, dual inhibitors were designed [75,76], i.e., compounds able to interact with the
binding regions of both metalloenzymes. Some amino acids were investigated as the structural backbone
of the new dual inhibitors; the derivatization of the carboxy and amino moieties gave sulfonylated
amino acid hydroxamates and N-alkyloxy amino acid hydroxamates (general formulas 42–44, Figure 20).
Compounds carrying both a hydroxamic and a protic-sulfonyl groups are, therefore, provided with two
different chelating moieties that could potentially interact with both metalloenzymes. Compounds 42
were strong dual inhibitors with Ki values in the low-medium nanomolar range, their inhibitory properties
against the two enzymes depending on some structural features [75]. For instance, compounds 42 carrying
a NH moiety (X = H) were more active on CA (isoform I, II and IV) than on MMPs (isoforms 1, 2, 8 and 9).
When X was a benzyl group, a potent activity was found on both enzymes, while a substituent on the
benzyl moiety almost abolished activity on CAs. Unfortunately, these substances were not tested on the
tumor-associated CA isoforms (IX and XII).
Compounds 43 and 44 were in general less potent on both hCAs and MMPs, probably due to the
complete absence of protic sulfonyl moiety that could behave as ZBG [76].
These studies confirm that amino acids, by showing good synthetic properties, are interesting
synthons also for the design of hybrid inhibitors, where an important need is the possibility to easily
modify many positions with different kind of substituents.
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Figure 20. Dual Matrix Metalloproteinase–Carbonic Anhydrase (MMP–CA) inhibitors.
7. Other Approaches
Especially from a synthetic point of view, another interesting approach to the design of novel
CAIs is the one reported in a paper by Korkmaz N. et al. [77]. These researchers, aiming to investigate
innovative inhibitors, synthesized a series of thiourea derivatives lacking a classic ZBG. As we can
note from general structures 45 and 46 in Figure 21, there are not pharmacophoric moieties that could
be immediately associated with an inhibitory activity on the enzyme. Nevertheless, micromolar Ki
values were measured for these series of compounds against hCA I and II. By analysing the structures,
we can observe that lipophilic amino acids were used as linker between two aromatic portions. For 46,
the amino acid carboxy group reacted with o-phenylendiamine giving a benzimidazole ring. Therefore,
compounds 46 can be considered as amino acid derivatives only from the synthetic point of view,
since the carboxy group is lost with the formation of the heterocyclic ring. Compounds 45 and 46 were
not extremely potent, but these synthetic pathways could be interesting for the side derivatization of
sulfonamidic molecules.
Figure 21. Thiourea CAIs built from amino acids.
Another scaffold lacking a classic chelating moiety is Probenecid, a drug used to treat gout and
hyperuricemia. Probenecid, probably thanks to the free carboxy group that coordinates the zinc
ion, possesses a weak inhibitory activity against CAs. Mollica et al. [78] investigated the effects of
adding different L-amino acid, obtaining probenecid-based amide derivatives (general formula 47,
Figure 22). This modification shifted the carboxy group away from the aromatic ring and introduced
a chiral linker. With the aim of studying the impact of the chemical modification of this terminal
COOH, these researchers also synthesized the corresponding primary amides. All the compounds
showed an interesting profile, their inhibitory activity against hCA IX and XII being higher than against
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the off-target isozymes hCA I and II. The transformation of the COOH group into CONH2 was also
interesting, resulting in a remarkably lower affinity against hCA II. As an example, both the methionine
derivatives 47a and 47b were very active against the two tumor-associated isoforms, but while the
carboxy derivatives possess a low residual activity against hCA I and II, the corresponding amide is
completely inactive toward these isoforms. This paper provides a useful overview of the application
of the “amino acid tail approach” to an atypical zinc-chelating molecule, confirming the synthetic and
pharmacological benefits that could be obtained from this method.
Figure 22. Probenecid amide derivatives.
In this section we report also the paper published by Fidan et al. [79], in which four aromatic
sulfonamides were directly functionalized on the amidic NH2 group with glycine and phenylalanine
(general formula 48, Figure 23). The derivatization of the zinc binding group with substituents able
to interact with the amino acids of the catalytic site was aimed at obtaining an enhancement in the
activity of these secondary sulfonamides. However, it must be recalled that the architecture of the
active site is very well conserved among the different CA isoforms, so this modification may not confer
selectivity to such derivatives. In general, the new compounds did not show a better inhibition profile
against hCA I and II as compared to their primary sulfonamide precursors. A substitution directly on
the ZBG, probably due to steric hindrance, seems not to be a convenient way to enhance the potency of
this kind of sulfonamides. Despite these negative results, this approach should be further investigated,
maybe with longer linkers between the sulfonamidic nitrogen and the pendants.
Figure 23. Glycine and phenylalanine N-sulfonamides studied by Fidan et al. [79].
Chiral pool synthesis was used by Chiaramonte et al. in order to prepare enantiopure
CA inhibitors [23]. Starting from L- or D-phenylalanine, both enantiomers of two series of
2-benzylpiperazines (49 and 50, Figure 24), carrying a sulfamoyl-benzoic moiety as ZBG, were obtained.
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The amino acid was directly used to build the piperazine scaffold, allowing the stereochemical control
of the side benzyl group. With this method, it was possible to take advantage of the versatile synthetic
properties of the synthon: the reduction of the intermediate diketopiperazine 51 converted the amino
acid into an alkyl derivative without affecting the absolute configuration. The piperazines were
further decorated on one nitrogen atom with the ZBG and with different alkyl/acyl/sulfonyl groups
on the other one, with the aim to look for selectivity toward the CA isoforms. All the synthesized
products were able to inhibit four pharmacological-relevant CA isozymes (hCA I, II, IV and IX),
showing Ki values ranging from low nanomolar to micromolar; hCA IX was the least sensitive isoform.
The hydrochloric salts of two basic piperazines (49a and 50a, Figure 24), showing very good water
solubility, were then selected for in-vivo tests in a rabbit model of glaucoma. Both derivatives were
able to reduce IOP with a potency and efficacy similar to the reference drug dorzolamide, confirming
that this series is promising for the development of new anti-glaucoma agents. The binding mode was
further investigated with X-ray analysis and the structure of the complex of compound 49b, bound in
the hCA I active site, was solved (PDB code 6EVR). In the image, reported in Figure 1b (Section 1), it is
possible to appreciate the interaction between the sulfonamidic group and the Zn2+, while the benzyl
group is deeply inserted in the lipophilic cavity of the enzyme, where it establishes Van der Waals
interactions with some hydrophobic amino acid residues. This synthetic method allowed the building
of a chiral piperazine scaffold, incorporating the aminoacid-skeleton. Starting from different amino
acids, it should be possible to modify the nature of this substituent and at the same time to control
its stereochemistry.
Figure 24. Piperazine derivatives studied by Chiaramonte et al. [23].
8. Conclusions
Amino acids are useful synthons. Thanks to their characteristics, there are several potential
applications in chemical synthesis. The possibility of using both proteinogenic and non-proteinogenic
amino acids allow the preparation of many related derivatives, where the different side chains
modulate the properties. The research of new CAIs or the structural modification of existing inhibitors
is a dynamic field with many perspectives but also a lot of still unsolved challenges, the most
important being the lack of selectivity of sulfonamides. The use of amino acids, or their derivatives,
could sometimes provide a smart solution to both synthetic and pharmacological problems.
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